Clinical trials: Chemotherapy-Related Nausea and/or Vomiting
- Condition Chemotherapy-Related Nausea and/or Vomiting
- Funder type Industry (pharma, biotech, devices)
Chemotherapy-Induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology…
- Trial name
- EVOLVE_CINV (NCT03649230)
- Testing
- 300mg netupitant/0.5mg palonosetron hydrochloride
- Where
- 17 sites in Canada
- Volunteers
- 207 people
- Sponsor
- Purdue Pharma, Canada
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea, Vomiting
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to determine whether palonosetron is tolerate and effective in preventing chemotherapy-induced nausea and vomiting in oriental population.
- Conditions
- Nausea, Vomiting, Chemotherapy
- Trial name
- NCT00503386
- Testing
- Palonosetron, Granisetron
- Where
- 6 sites in China
- Volunteers
- 144 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Chemotherapy-induced Nausea and Vomiting
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of single increasing doses of intravenously administered rolapitant in healthy male and female subjects.
- Trial name
- NCT02382666
- Testing
- Rolapitant
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Chemotherapy-Induced Nausea and Vomiting
Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy
To compare palonosetron with granisetron hydrochloride as a control in the efficacy of intravenous single dose in preventing acute and delayed gastro-intestinal disorders, such as nausea and vomiting induced by highly emetogenic…
- Trial name
- NCT00359567
- Testing
- palonosetron, granisetron hydrochloride
- Where
- Japan
- Volunteers
- 1,140 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Nausea, Vomiting
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092196
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days
- Volunteers
- 820 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic…
- Trial name
- NCT04054193
- Testing
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Where
- 26 sites in United States, Greece and 7 more
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
- Trial name
- NCT01596400
- Testing
- granisetron transdermal system, Granisetron IV
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-induced Nausea and Vomiting (CINV)
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
- Trial name
- NCT00952341
- Testing
- aprepitant, dexamethasone, granisetron
- Volunteers
- 421 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone.
- Trial name
- NCT01363479
- Testing
- Oral palonosetron, I.V. palonosetron, Dexamethasone
- Where
- 79 sites in United States, Argentina and 10 more
- Volunteers
- 743 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple…
- Trial name
- NCT02434861
- Testing
- Rolapitant, Digoxin, Sulfasalazine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Chemotherapy-Induced Nausea and Vomiting
Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00972595
- Testing
- ondansetron clinical trial formulation, ondansetron marketed formulation
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to assess the efficacy and safety of SP-01 in chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic (ME or HE) multi-day…
- Trial name
- NCT01937156
- Testing
- SP-01 (Granisetron Transdermal Delivery System), Granisetron Hydrochloride Tablet
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Solasia Pharma K.K.
Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Prevention of Unmitigated Chemotherapy-induced Emesis
Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to patient care and continues to decrease quality of life.
- Trial name
- PUCE (NCT03996863)
- Testing
- Otoband
- Where
- United States
- Sponsor
- Otolith Labs
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
The purpose of this study is to evaluate the efficacy and safety of fosaprepitant (MK-0517) plus ondansetron versus ondansetron alone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric participants…
- Trial name
- NCT02519842
- Testing
- Fosaprepitant, Ondansetron, Dexamethasone
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring…
- Trial name
- NCT00642512
- Testing
- dronabinol, ondansetron, dronabinol/ondansetron
- Where
- 43 sites in United States
- Volunteers
- 64 people
- Sponsor
- Solvay Pharmaceuticals
Chemotherapy Induced Nausea and Vomiting
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients…
- Trial name
- NCT06065722
- Testing
- Akynzeo
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Simon Williamson Clinic
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Postoperative, Nausea With Vomiting Chemotherapy-Induced
Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover bioequivalence study with a 7-day washout between periods. Each treatment was administered after an overnight (10 hours) fast.
- Trial name
- 01905/08-09 (NCT01217190)
- Testing
- Ondansetron (ODFS), Zofran (ODT)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MonoSol Rx